Eye Condition Clinical Trials in the UK (2026): Glaucoma, Macular Degeneration and Vision Research
Eye conditions like glaucoma and macular degeneration are leading causes of vision loss in the UK, particularly among older adults. Clinical trials are testing revolutionary new approaches — from gene therapy that could eliminate the need for regular eye injections to sustained-release implants that manage glaucoma without daily drops.
Macular Degeneration: Ending the Injection Burden
Anti-VEGF injections have saved sight for hundreds of thousands of UK patients with wet age-related macular degeneration (AMD). But the burden of monthly or bi-monthly injections is significant. UK trials are testing longer-acting anti-VEGF drugs that could extend dosing to every 3-6 months, port delivery systems (tiny implants that continuously release medication), and gene therapy approaches that could enable the eye to produce its own anti-VEGF protein, potentially eliminating injections entirely.
Glaucoma: Beyond Daily Eye Drops
Daily eye drops have been the mainstay of glaucoma treatment for decades, but adherence is a major problem — up to half of patients do not use their drops consistently. Trials are testing sustained-release implants that deliver medication over months, minimally invasive glaucoma surgery (MIGS) devices that can be implanted during cataract surgery, and neuroprotective drugs that preserve the optic nerve independent of intraocular pressure reduction.
Inherited Retinal Diseases and Gene Therapy
Inherited retinal diseases, though rare individually, collectively affect thousands of UK patients. Gene therapy is particularly promising for these conditions because the eye is an accessible target. UK trials at centres including Moorfields Eye Hospital and Oxford Eye Hospital are testing gene therapies for conditions including choroideremia, X-linked retinoschisis, and Leber congenital amaurosis. Some have already shown vision improvements in early trials.